Cell-free DNA for treatment monitoring and outcome predictor in head and neck cancer
Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO. Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion.
Predicting Treatment Outcomes in Immunotherapy
Weiss, G. et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.
Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).
Predicting Treatment Outcomes in Chemotherapy
Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.
Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.
Prostate Cancer Blood Test
Schütz, E., et al. Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer. Clinical Chemistry 2015; 61: 239-248.
Tumor-specific cell free DNA (cfDNA) present in serum and plasma provides a real-time, easily accessible surrogate. We demonstrated variations in the number of cfDNA sequences circulating in the serum of patients with prostate cancer compared with healthy controls.
Cohort Study in LiverTx
Schütz E. et al. Graft-Derived Cell-Free DNA – a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation PlosMed (2017;) doi:10.1371/journal.pmed.1002286
Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker.
Rectal Cancer Treatment Outcome Predictions
Beck, J. et al. Comprehensive analyses of rectal cancer genomes to reveal copy number variations as potential predictor of induction therapy efficacy. J ClinOncol 32, 2014 (suppl; abstr e14549).
Genome profiling of individual tumors is provided by high-throughput sequencing and is about to enter routine clinical practice with impact on treatment decisions and tumor classification (NIH [2014] The Cancer Genome Atlas).
HPV Genotyping and Treatment Outcome Predictions
Urnovitz, HB et al. Detection of novel HPV mutations and chromosomal number imbalance (CNI) in laryngeal cancer using next-generation sequencing (NGS). J ClinOncol 32:5s, 2014 (suppl; abstr 6072).
The detection of novel HPV mutations and CNI analysis in a single NGS run on HPV-related diseases provides important information into viral-host dynamics while generating biomarkers that can be correlated with treatment outcomes.
Breast Cancer Liquid Biopsy Screening Test
Beck, J. et al. Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. J ClinOncol 31, 2013 (suppl; abstr 11013).
Using comparative massive parallel sequencing of cfDNA from cancer patients vs. controls, we were able to show that a 16-region model based on CNV, is useful to distinguish patients with breast cancer from matched controls.
Animal Model for MRD in Breast Cancer
Beck, J. et al. Structural variation in mammary carcinomas and their detection in cell-free plasma DNA. PLOS One 2013 (10.1371/journal.pone.0075485).
Mammary tumors are the most frequent cancers in female dogs exhibiting a variety of histopathological differences. There is lack of knowledge about the genomes of these common dog tumors. Five tumors of three different histological subtypes were evaluated.